Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Lucid Diagnostics (LUCD) EBITDA Margin (2021 - 2025)

Lucid Diagnostics' EBITDA Margin history spans 5 years, with the latest figure at 1563.13% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 259697.0% year-over-year to 1563.13%; the TTM value through Dec 2025 reached 257.68%, up 80199.0%, while the annual FY2025 figure was 259.19%, 80045.0% up from the prior year.
  • EBITDA Margin reached 1563.13% in Q4 2025 per LUCD's latest filing, up from 979.92% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 4092.52% in Q2 2021 to a low of 18917.11% in Q3 2022.
  • Average EBITDA Margin over 5 years is 3379.88%, with a median of 1283.96% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: plummeted -1566211bps in 2022, then soared 1749590bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 3747.0% in 2021, then tumbled by -257bps to 13370.54% in 2022, then skyrocketed by 92bps to 1101.25% in 2023, then increased by 6bps to 1033.83% in 2024, then soared by 251bps to 1563.13% in 2025.
  • Per Business Quant, the three most recent readings for LUCD's EBITDA Margin are 1563.13% (Q4 2025), 979.92% (Q3 2025), and 948.67% (Q2 2025).